Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Essink
M E
ME
Dept. of Internal Medicine, Hematology/Oncology, University of Münster, FRG.
Hiddemann
W
W
von Eiff
M
M
Büchner
T
T
van de Loo
J
J
D000380:Agranulocytosis / Q000139:chemically induced / Q000503:physiopathology*; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003864:Depression, Chemical; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000150:complications / Q000188:drug therapy; D015993:Life Tables; D008942:Mitoxantrone / Q000008:administration & dosage; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology; D013866:Thioguanine / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced / Q000503:physiopathology*
D000935:Antifungal Agents; D003561:Cytarabine; D008942:Mitoxantrone; D013866:Thioguanine; D003630:Daunorubicin